Activation of Protein Kinase C Delta following Cerebral Ischemia Leads to Release of Cytochrome C from the Mitochondria via Bad Pathway by Dave, Kunjan R. et al.
Activation of Protein Kinase C Delta following Cerebral
Ischemia Leads to Release of Cytochrome C from the
Mitochondria via Bad Pathway
Kunjan R. Dave
1, Sanjoy K. Bhattacharya
3, Isabel Saul
1, R. Anthony DeFazio
1, Cameron Dezfulian
1,4,
Hung Wen Lin
1, Ami P. Raval
1, Miguel A. Perez-Pinzon
1,2*
1Cerebral Vascular Disease Research Center, Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, United States of
America, 2Neuroscience Program, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, United States of America, 3Bascom Palmer Eye Institute,
Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, United States of America, 4Department of Medicine, Leonard M. Miller School of Medicine,
University of Miami, Miami, Florida, United States of America
Abstract
Background: The release of cytochrome c from the mitochondria following cerebral ischemia is a key event leading to cell
death. The goal of the present study was to determine the mechanisms involved in post-ischemic activation of protein
kinase c delta (dPKC) that lead to cytochrome c release.
Methods/Findings: We used a rat model of cardiac arrest as an in vivo model, and an in vitro analog, oxygen glucose
deprivation (OGD) in rat hippocampal synaptosomes. Cardiac arrest triggered translocation of dPKC to the mitochondrial
fraction at 1 h reperfusion. In synaptosomes, the peptide inhibitor of dPKC blocked OGD-induced translocation to the
mitochondria. We tested two potential pathways by which dPKC activation could lead to cytochrome c release:
phosphorylation of phospholipid scramblase-3 (PLSCR3) and/or protein phosphatase 2A (PP2A). Cardiac arrest increased
levels of phosphorlyated PLSCR3; however, inhibition of dPKC translocation failed to affect the OGD-induced increase in
PLSCR3 in synaptosomal mitochondria suggesting the post-ischemic phosphorylation of PLSCR3 is not mediated by dPKC.
Inhibition of either dPKC or PP2A decreased cytochrome c release from synaptosomal mitochondria. Cardiac arrest results in
the dephosphorylation of Bad and Bax, both downstream targets of PP2A promoting apoptosis. Inhibition of dPKC or PP2A
prevented OGD-induced Bad, but not Bax, dephosphorylation. To complement these studies, we used proteomics to
identify novel mitochondrial substrates of dPKC.
Conclusions: We conclude that dPKC initiates cytochrome c release via phosphorylation of PP2A and subsequent
dephosphorylation of Bad and identified dPKC, PP2A and additional mitochondrial proteins as potential therapeutic targets
for ischemic neuroprotection.
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Introduction
The release of mitochondrial cytochrome c into the cytosol
following cerebral ischemia was first observed in the late 1990’s
[1,2], and is a key event that initiates the apoptotic cell death
pathway while indirectly participating in the necrotic pathway
leading to neuronal death [3]. Besides activating the apoptotic
cascade, release of mitochondrial cytochrome c can also contribute
to mitochondrial dysfunction including lower activity of mito-
chondrial respiratory chain complex IV [4]. The factors that
contribute to mitochondrial cytochrome c release following
cerebral ischemia include activation of pro-apoptotic Bcl-2 family
of proteins (e.g Bad Bax, and Bak), opening of the mitochondrial
permeability transition pore, activation of heat shock proteins, and
increases in calcium levels, among others (see recent reviews for
details: [5]). However, the precise mechanism by which cyto-
chrome c is released from the mitochondria following cerebral
ischemia is not fully understood [6].
Protein kinase c delta (dPKC) can initiate pro-apoptotic
pathways by direct effects on the mitochondria [7,8]. For example,
dPKC phosphorylates mitochondrial phospolipid scramblase 3
(PLSCR3), resulting in increased cardiolipin expression on the
mitochondrial outer membrane which facilitates apoptosis in
HeLa cells [9]. Increased cardiolipin presence on the mitochon-
drial outer membrane recruits t-Bid (truncated BH3 interacting
domain death agonist) which in turn results in formation of Bax/
Bak pores through which cytochrome c release may occur
[9,10,11]. Another target of dPKC phosphorylation is protein
phosphatase 2A (PP2A) which may contribute to apoptosis by
dephosphorylating Bad resulting in heterodimer formation and
inactivation of Bcl-2 and Bcl-xL [12]. The inactivation of Bcl-2
and Bcl-xL permit the release of Bax which, when dephosphor-
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permitting cytochrome c release [11,13]. Thus dPKC activation
may result in phosphorylation of targets both within and outside
the mitochondria resulting in cytochrome c release and apoptosis.
By utilizing in vivo and in vitro models of cerebral ischemia, we
and others have demonstrated that dPKC is activated (translocat-
ed from soluble to the particulate membrane fraction) following
cerebral ischemia [14,15,16]. When activation of dPKC is
attenuated with a dPKC-specific peptide inhibitor (dV1-1), the
brain is protected from ischemic neuronal damage [14,15]. dPKC
activation has been implicated in ischemia/reperfusion-induced
injuries such as oxidative stress, apoptosis, and inflammation
[7,8,17]. In previous studies, we observed that release of
cytochrome c and activation of dPKC following cerebral ischemia
were closely correlated [14,15]. However, whether ischemia-
induced dPKC translocation participates in the release of
cytochrome c from mitochondria has not been defined.
The goal of the present study was to first test the hypothesis that
dPKC translocation/activation after cerebral ischemia could result
in cytochrome c release. We next tested two mechanistic
hypotheses whereby dPKC may mediate cytochrome c release
by: 1) phosphorylation/activation of PLSCR3 leading to targeting
of t-Bid and downstream cytochrome c release, and 2) activation of
dPKC phosphorylates PP2A leading to de-phosphorylation of pro-
apoptotic factors Bad and Bax. Finally, we used proteomics to
identify additional mitochondrial targets of dPKC which may be
phosphorylated upon its translocation.
Results
dPKC translocates to the mitochondria following in vivo
and in vitro cerebral ischemia
We first tested the hypothesis that cerebral ischemia results in
dPKC translocation from the cytosol to the mitochondria.
Previously, we had observed in this model of cardiac arrest (CA)
that cytochrome c is released at 1 h of reperfusion. Therefore, we
examined dPKC translocation to hippocampal mitochondria at
this time [15]. After 8 min of CA, hippocampal mitochondrial
fraction of dPKC was enhanced by 99% (n=4, p,0.05) as
compared to sham-operated animals (Figure 1A). To test whether
CA induced dPKC translocation is recapitulated in our in vitro
system, we induced OGD in synaptosomes in the presence of tat
carrier peptide (control vehicle for the dPKC inhibitor peptide)
and compared it with control (no ischemia) synaptosomes
(Figure 1B). OGD in synaptosomes doubled dPKC protein levels
in the mitochondrial fraction (n=5, p,0.05). This increase in
dPKC translocation was reversed by 85% (n=5, p,0.05) upon
OGD induction in the presence of dV1-1. Thus, dPKC
translocates to the mitochondria during the first hour of
reperfusion following in vivo and in vitro hippocampal neuronal
ischemia. The translocation was abolished in vitro using dV1-1.
dPKC mediates the release of cytochrome c following
OGD
Since we demonstrated dPKC translocation at 1 h of reperfu-
sion when cytochrome c release plateaus, we next sought to
determine if inhibition of translocation prevents cytochrome c
release. Rat hippocampal synaptosomes underwent 60 min of
OGD in the presence of dV1-1 or tat peptide with subsequent
measurements of cytosolic cytochrome c. These levels were
normalized to the cytosolic cytochrome c levels of control
synaptosomes incubated in glucose containing solution with room
Figure 1. dPKC translocates to the mitochondria following CA
and dPKC activation following OGD increases cytochrome c
release. A) Immunoblot of dPKC in hippocampal mitochondria of a rat
subjected to 8 min of CA and 1 h of reperfusion. Levels of dPKC
normalized against COXIV for loading control are expressed as
percentage from sham-operated (control) group. B) Immunoblots of
dPKC in mitochondria isolated from hippocampal synaptosomes
without ischemia or following 1 h oxygen glucose deprivation (OGD)
in presence of tat (control) or dPKC inhibitor (dV1-1). Levels of dPKC
normalized against COXIV for loading control are expressed as
percentage of control dPKC protein expression. C) Immunoblot of
cytochrome c in the soluble fraction of hippocampal synaptosomes
subjected to oxygen glucose deprivation (OGD) in the presence of tat,
dV1-1 or okadaic acid. Levels of cytochrome c normalized against b-
actin for loading control are expressed as percentage of OGD in the
presence of tat (control) group. *, p,0.05 v. sham or tat treated group.
doi:10.1371/journal.pone.0022057.g001
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peptide resulted in a 268% increase in cytochrome c release from
the mitochondria (n=5) as compared to control. Inhibition of
dPKC translocation (via dV1-1) resulted in cytochrome c release
similar to control and significantly less than untreated OGD
synaptosomes (n=5, p,0.05; Figure 1C). Thus, dPKC inhibition
prevents cytochrome c release favoring neuronal survival.
Phospholipid scramblase 3 (PLSCR3) phosphorylation
following cerebral ischemia is not due to dPKC
activation/translocation
We hypothesized that post-ischemic dPKC phosphorylation of
PLSCR3 could increase cardiolipin availability on the outer
membrane of the mitochondria facilitating cytochrome c release
through targeting of t-Bid and subsequent activation of Bax and
Bak [10]. Indeed, CA led to a 56% (n=4, p,0.05) increase in
phospho-PLSCR3 (p-PLSCR3) in mitochondrial fraction as
compared to sham-operated rats (Figure 2A) and an even larger
increase in PLSCR3 phosphorylation (110% compared to control,
p,0.05; Figure 2B) was noted in vitro. However, PLSCR3
phosphorylation did not change significantly when dPKC was
inhibited during OGD (Figure 2B). Thus, dPKC activation/
translocation was dissociated from phosphorylation of PLSCR3
and fails to mechanistically explain the increase in cytochrome c
release following cerebral ischemia (Figure 1C).
Protein Phosphatase 2A activation leads to release of
cytochrome c
dPKC activates PP2A via phosphorylation [12] although it is
unclear whether this is due to dPKC translocation to yet
uncharacterized cytoskeletal receptors in close proximity to
PP2A. PP2A has a number of known downstream targets, which
we hypothesized could modulate cytochrome c release. To test this
hypothesis, synaptosomes were subjected to 60 min of OGD in the
presence of two protein phosphatase inhibitors in separate
experiments: okadaic acid 0.1 nM) and calyculin (10 nM), which
are potent inhibitors of both PP1 and PP2A [18]. The Ki of
okadaic acid is 0.1 nM for PP2A vs. 10 nM for PP1, making it
more specific for PP2A, whereas the Ki of calyculin is 10-fold
higher for PP1 as compared to PP2A [18,19]. Okadaic acid
lowered OGD-induced cytochrome c release by 52% (n=5,
p,0.05) (Figure 1C) as compared to vehicle OGD group. In
contrast, calyculin lowered OGD-induced cytochrome c release by
an insignificant 15% (n=5) (Figure 1C) as compared to vehicle
OGD group. These results suggest that cerebral ischemia-induced
PP2A activation triggers cytochrome c release most likely via
dephosphorylation of downstream targets.
PP2A activation leads to release of cytochrome c via Bad
and Bax pathway
We next hypothesized that PP2A activation following dPKC-
mediated phosphorylation could result in dephosphorylation of
pro-apoptotic proteins Bad and Bax, both of which would be
expected to result in increased cytochrome c release [20,21]. The
level of Bad and Bax phosphorylation was determined at 1 h of
reperfusion in rat hippocampal homogenates subjected to CA
(Figure 2C and D). We observed that the levels of phospho-Bad
and phospho-Bax were decreased by 46% (n=4, p,0.01) and
49% (n=4, p,0.05), respectively as compared to sham-operated
rats. To test whether the Bad and Bax de-phosphorylation
observed in vivo resulted from dPKC induced phosphorylation/
activation of PP2A, we tested the impact of synaptosomal OGD in
the presence of either dV1-1 or the PP2A inhibitor okadaic acid
(0.1 nM). Both inhibitors (dV1-1 and okadaic acid) decreased
OGD-induced Bad de-phosphorylation (i.e. led to increased
phosphorylation) by 170% (n=5, p,0.05) and 101% (n=5),
respectively as compared to OGD in the presence of tat peptide
group (Figure 3A). Calyculin had a less significant (54%) effect on
Bad de-phosphorylation. However, the effect of all inhibitors on
Bax phosphorylation was marginal and insignificant (Figure 3B).
These results suggest that dPKC activation following cerebral
ischemia phosphorylates PP2A resulting in subsequent Bad, but
not Bax, de-phosphorylation ultimately resulting in increased
release of cytochrome c.
Additional substrates for dPKC within the mitochondria
Although it is established that dPKC initiates apoptosis via the
mitochondrial pathway [15,22,23], until now only four mitochon-
drial substrates (d subunit of Fo-F1 ATPase, pyruvate dehydro-
genase kinase -2, phospholipid scramblase 3 and acid sphingomy-
elinase) for dPKC have been identified. Since PLSCR3 did not
appear to be an important mitochondrial target of translocated
dPKC, we sought to identify additional potential mitochondrial
substrates for dPKC. Additional phospho-proteins were identified
in mitochondria isolated from synaptosomes treated with dPKC
activator peptide (ydRACK) or tat carrier peptide (control). dPKC
can translocate to membrane/particulate fraction by ydRACK
induced dPKC activation [24]. Using the Pro-Q Diamond
phospho-protein gel stain, we noticed distinct bands of molecular
weight ,45, 30 and 7 kDa which were enriched by 48% (p,0.05),
45% (p,0.05) and 199% (p,0.001) (n=4 each) with ydRACK
treatment as compared to control (Figure 4). Protein identification
was performed using MS/MS analysis which identified numerous
mitochondrial proteins in the first two bands (,45 and 30 kDa)
which are listed in Table 1. Owing to technical challenges we were
unable to identify proteins present in the third band (,7 kDa).
This list serves as a source for future investigations regarding
mitochondrial targets of dPKC activated by cerebral ischemia.
Discussion
The precise signaling pathways that lead to cyotochrome c
release from mitochondria after ischemia have not been fully
elucidated. In the present study, we demonstrate that cerebral
ischemia induces mitochondrial translocation of dPKC associated
with cytochrome c release and that inhibition of dPKC
translocation prevents this pro-apoptotic event. We next evaluated
4 distinct mechanistic hypotheses to explain this finding as
summarized in Figure 5.
We had initially hypothesized that activated mitochondrial
dPKC would phosphorylate PLSCR3 thereby increasing outer
membrane cardiolipin which would recruit t-Bid and subsequently
Bax and Bak, permitting pore formation and cytochrome c
extrusion [10].However, our resultsdonotsupportthis mechanism.
Rather, we have identified a number of additional mitochondrial
targets of dPKC translocation/activation which may explain the
mechanism of cytochrome c release and apoptosis. Since dPKC is
capable of targeting additional proteins outside the mitochondria,
we chose to examine a pathway known to be regulated in neurons
by dPKC and important in the control of apoptosis. Our results
demonstrate that cerebral ischemia dephosphorylates Bad and Bax,
eventsthatpromote apoptosisthroughformationofamitochondrial
pore to permit the release of cytochrome c. We demonstratethat the
dephosphorylation of Bad but not Bax appears to be under the
control of dPKC and PP2A activation.
In the present study, we used asphyxial CA in rats to model
cerebral ischemia and demonstrated at each step that in vitro OGD
PKC Delta and Post-Ischemic Cytochrome C Release
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Synaptosomes are considered to be the simplest possible
anucleated, neuronally derived mammalian ‘‘mini-cell’’ (see review
for details [25]). Synaptic mitochondria play a significant role in
neurotransmitter release by regulation of cytosolic calcium [26]
and thus would be expected to be highly susceptible to cerebral
ischemia/reperfusion. In the present study, we observed that
dPKC translocated to the synaptic mitochondria with in vitro
ischemia and that this process could be efficiently inhibited with
dV1-1. Since synaptic mitochondria are neuronally derived
(excluding mitochondria from glia and neuronal body), we are
limited in our ability to extrapolate our findings to the whole brain.
In earlier studies we reported that dPKC is activated
(translocated from soluble to particulate fraction) following
cerebral ischemia [14,15]. In the present study, we demonstrate
that mitochondria are one of the particulate fractions to which
dPKC translocates following cerebral ischemia. This translocation
may be initiated by the formation of reactive oxygen species,
Figure 2. Phospholipid scramblase 3 (PLSCR3), Bad and Bax phosphorylation following cerebral ischemia. A) Immunoblot of p-PLSCR3
and PLSCR3 in hippocampal mitochondria of a rat subjected to 8 min of CA and 1 h of reperfusion. B) Immunoblot of p-PLSCR3 and PLSCR3 in
synaptosomes subjected to oxygen glucose deprivation (OGD) in the presence of tat or dV1-1. Immunoblots (representative images are shown at the
top of each bar) were subjected to densitometric analyses, and levels of p-PLSCR3 were normalized against PLSCR3 for loading control is expressed as
percentage of OGD in the presence of tat (control) group. Immunoblot of (C) p-Bad and (D) p-Bax in hippocampal homogenate of a rat subjected to
8 min of CA and 1 h of reperfusion. Levels of p-Bad and p-Bax normalized against total-Bad and total-Bax, respectively are expressed as percentage of
sham operated (control) group. *, p,0.01 v. sham. *, p,0.05 v. sham or tat treated group.
doi:10.1371/journal.pone.0022057.g002
PKC Delta and Post-Ischemic Cytochrome C Release
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22057reactive nitrogen species and diacylglycerol formation [27]. Non-
specific translocation of dPKC to mitochondria as a result of the
isolation procedure may be ruled out due to the presence of lower
levels of dPKC in shams in vivo and control synaptosomes in vitro.
Oxidative stress-induced translocation of dPKC to mitochondria
has been shown to be associated with loss of mitochondrial
membrane potential and mitochondrial cytochrome c release
[8,28,29,30]. In the heart, ischemia/reperfusion results in
diminished mitochondrial respiration which is restored by
reperfusion in the presence of dPKC inhibitor. This contention
is supported by our earlier study where we found that suppressed
rate of respiration in presence of complex IV substrates at early
reperfusion (30 min) following global cerebral ischemia was due to
the release of mitochondrial cytochrome c [4]. We observed
similar results using a rat model of asphyxial cardiac arrest, where
we found that mitochondrial cytochrome c was released at 1 h of
reperfusion following 8 min of cardiac arrest [15]. The present
study thus provides potential targets for dPKC whose translocation
to mitochondria early after ischemia is associated with mitochon-
drial dysfunction and mitochondrial cytochrome c release.
Since we observed that OGD-induced cytochrome c release was
prevented by inhibition of dPKC, we explored possible pathways
by which cerebral ischemia-induced dPKC activation led to the
release of cytochrome c. First we determined whether dPKC
exerted its effect by direct interaction with mitochondrial targets.
Our first candidate was the phospholipid scramblase – 3
(PLSCR3), a known mitochondrial target of dPKC phosphoryla-
tion [31,32]. PLSCR3, a member of phospholipid scramblase
family of proteins, transports cardiolipin from the inner to the
outer membrane of the mitochondria. Cytochrome c is bound to
the outer surface of the inner mitochondrial membrane by
associating with cardiolipin [33]. PLSCR3 had also been identified
as a regulator of cardiolipin de novo biosynthesis [34]. Previous
studies demonstrated that cardiolipin and cytochrome c interaction
is a critical factor determining the amount of cytochrome c release
during apoptotic stimuli [35,36]. It is possible that following
cerebral ischemia, PLSCR3, modified by dPKC, may result in
impaired cardiolipin – cytochrome c interaction leading to
cytochrome c release.
We observed that PLSCR3 phosphorylation was indeed
increased following in vivo cerebral ischemia. However, in our
synaptosomal model, we were unable to block OGD-induced
increase in PLSCR3 phosphorylation by dV1-1 (dPKC-specific
inhibitor peptide) at the same dose that inhibited cytochrome c
release. Although previous studies concluded that PLSCR3 can be
phosphorylated by dPKC; however, these studies used either
general PKC activators (phorbol ester) or CMV promoter-driven
dPKC overexpression (supra-physiological levels of dPKC)
[31,32]. No information is available on the effect of dPKC on
PLSCR3 phosphorylation under physiological levels of dPKC or
specific activation of dPKC without affecting other PKC isoforms.
It is plausible that dPKC phosphorylates PLSCR3 in other cell
types or neuronal compartments outside the synaptosome, as
suggested by these studies, or that other PKC isoforms participate
in PLSCR3 phosphorylation with ischemia. Our results suggest
that PLSCR3 phosphorylation does occur in hippocampus in vivo
but that dPKC inhibition does not block this process based on our
in vitro data. Limitations exist when extrapolating an in vitro model
results to in vivo findings, even when the in vitro model correlates
well with the in vivo findings as we have already demonstrated.
Because dPKC-induced cytochrome c release was independent
of mitochondrial PLSCR3 phosphorylation, we next examined
Figure 3. dPKC activation following OGD decreases Bad
phosphorylation via PP2A activation. A) Immunoblot of p-Bad in
hippocampal synaptosomes subjected to oxygen glucose deprivation
(OGD) in the presence of tat, dV1-1 or okadaic acid. Immunoblots
(representative images are shown at top of each bar) were subjected to
densitometric analyses, and levels of p-Bad were normalized against
total-Bad for loading control is expressed as percentage of OGD in the
presence of tat (control) group. B) Immunoblot of p-Bax in hippocampal
synaptosomes subjected to oxygen glucose deprivation (OGD) in the
presence of tat, dV1-1 or okadaic acid. Immunoblots (representative
images are shown at top of each bar) were subjected to densitometric
analyses, and levels of p-Bax were normalized against total-Bax for
loading control is expressed as percentage of OGD in the presence of
tat (control) group. * p,0.05 v. tat treated group.
doi:10.1371/journal.pone.0022057.g003
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demonstrated that the phospho-protein signal of three protein
bands were increased in mitochondria isolated from synaptosomes
treated with ydRACK. Proteomics analyses of these bands
revealed the presence of the following phosphoproteins: ubiquinol
cytochrome c reductase core protein 2, Fe-S protein 2, 3 and
Figure 4. dPKC induced increased protein phosphorylation. Mitochondria were isolated from hippocampal synaptosomes treated with tat or
ydRACK. Mitochondrial proteins were separated on a 4–20% polyacrylamide gel. (A) Images of gels stained with ProQ diamond or Coomassie blue to
detect phosphoproteins or total proteins, respectively. (B) Gel images were subjected to densitometric analysis for 5 bands (50 kDa, 45 kDa, 30 kDa,
25 kDa, and 7 kDa). Phosphoprotein signal was normalized against Coomassie blue stained gel signal. The results are expressed as percent of tat
treated group. *, p,0.05 v. tat treated group.
doi:10.1371/journal.pone.0022057.g004
Table 1. List of proteins identified in the proteomics study.
Accession NCBI NR Protein MW kDa Peptides identified Score Xcalibur
Band 45 kDa 55741544 Ubiquinol cytochrome c reductase core protein 2 48 30 100.19
58865384 NADH dehydrogenase (ubiquinone) Fe-S protein 2 53 14 70.26
60678254 Creatine kinase, mitochondrial 1, ubiquitous 47 14 40.24
158749584 Succinate-Coenzyme A ligase, beta subunit 50 7 40.21
57657 Pyruvate dehydrogenase E1 alpha form 1 subunit 43 7 40.19
54792127 Mitochondrial ATP synthase beta subunit 56 3 20.17
149029485 ATP synthase, alpha subunit, 50 2 20.15
18543177 Citrate synthase 52 3 10.15
Band 30 kDa 32189350 Solute carrier family 25, member 5 33 33 100.22
6679299 Prohibitin 30 19 80.27
47718004 Slc25a3 protein 40 11 60.20
1580888 2116232A 2-oxoglutarate carrier protein 34 10 52.24
157817227 NADH dehydrogenase (ubiquinone) Fe-S protein 3 30 10 40.21
9507245 Tyrosine 3-monooxygenase 28 3 20.24
157817027 Coiled-coil-helix-coiled-coil-helix domain containing 3 26 4 20.19
59808764 Nipsnap1 protein 33 4 20.18
51092268 NADH dehydrogenase (ubiquinone) flavoprotein 2 27 3 20.17
89573817 Succinate dehydrogenase complex subunit B 27 3 20.13
doi:10.1371/journal.pone.0022057.t001
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subunit of succinate-coenzyme A ligase, E1 alpha form 1 subunit
of pyruvate dehydrogenase (PDH), alpha and beta subunits of
ATP synthase, citrate synthase, and prohibitin [37,38].
An earlier study using in vivo models of cardiac ischemia/
reperfusion demonstrated that dPKC activation (translocation to
mitochondria) was responsible for decreased pyruvate dehydroge-
nase (PDH) activity following ischemia/reperfusion [39]. Their
results support the hypothesis that activated dPKC interacts with
and phosphorylates pyruvate dehydrogenase kinase (PDK)-2,
which in turn phosphorylates the alphaE1 subunit of PDH,
resulting in lower PDH activity. Based on our results and the
earlier study, we hypothesize that the E1 alpha subunit of PDH is
phosphorylated after ischemia/reperfusion-induced dPKC activa-
tion resulting in lower PDH activity in the brain [40,41,42].
Earlier studies demonstrated that ischemia/reperfusion resulted in
lower ATP synthase and citrate synthase activities in the brain
[43,44,45]. It is possible that ischemia/reperfusion-induced
phosphorylation of ATP synthase (alpha and/or beta subunit)
and citrate synthase via dPKC activation may be responsible for
lower activities of these two enzymes. However, further investiga-
tion is required to support this hypothesis.
Our results suggest that prohibitin could be one of the
mitochondrial substrates for dPKC [46]. Prohibitins are present
in inner membrane of the mitochondria and forms multimeric ring
complexes. Prohibits regulates mitochondrial fusion by regulating
processing of the dynamin-like GTPase OPA1 [46,47]. It is
possible that dPKC-induced prohibitin phosphorylation may be
responsible for cerebral ischemia-induced mitochondrial fission
and suppressed mitochondrial respiration.
Mitochondrial cytochrome c release and apoptosis are also
modulated by proteins located outside the mitochondrion. A
prime example are the bcl-2 family proteins such as Bad and Bax
whose activation and mitochondrial translocation are shown to
induce cytochrome c release following apoptotic stimuli after
cerebral ischemia [48,49,50,51,52,53]. One potential pathway by
which these molecules are activated is by de-phosphorylation via
phosphatase [20,21] such as PP2A. Zhang and colleagues
demonstrated that PP2A activity is enhanced up to 3.4 fold
following cerebral ischemia [54]. PP2A can also be activated by
dPKC-induced phosphorylation [12]. PP2A is present in cytosol,
membrane, cytoskeleton, and nuclear compartments, while dPKC
is present in cytosol and translocates to particulate/membrane/
cytoskeleton fraction following activation [55,56,57]. In which
sub-cellular compartments dPKC interacts with PP2A is not
known. In the present study, we were able to inhibit cerebral
ischemia-induced Bad dephosphorylation as well as cytochrome c
release by inhibiting dPKC or PP2A but not PP1 during ischemia.
The slight inhibition observed with calyculin may be the result of
PP2A effects, although 10-fold less than PP1. Our findings,
therefore, support our proposed mechanism that dPKC activation
via phosphorylation of PP2A results in cytochrome c release
through the dephosphorylation of Bad.
In conclusion, our study demonstrated that dPKC translocated to
mitochondria following cerebral ischemia/OGD. Post-ischemic
activation of dPKC was not responsible for increased PLSCR3
phosphorylation but may target other mitochondrial proteins
resultingin mitochondrial dysfunction and/orcytochrome c release.
dPKC activation following cerebral ischemia led to the release of
mitochondrial cytochrome c via the PP2A – Bad pathway.
Figure 5. Schematic diagram of the mechanism by which cerebral ischemia-induced dPKC activation leads to cytochrome c release.
Post-ischemic dPKC activation leads to activation of PP2A. Activated PP2A dephosphorylates Bad, but not Bax, which in turn release cytochrome c
from mitochondria. In addition, dPKC can also contribute to mitochondrial dysfunction by phosphorylating other mitochondrial target proteins.
doi:10.1371/journal.pone.0022057.g005
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Animals and Induction of cardiac arrest
All animal procedures were carried out in accordance with the
Guide for the Care and Use of Laboratory Animals published by
the National Institutes of Health and approved by the Animal
Care and Use Committee of the University of Miami (protocol #
09-050). For experiments with hippocampus from naı ¨ve animals,
male Sprague Dawley rats weighing 250–300 g were used. They
were sacrificed under isoflurane anesthesia and the hippocampi
were dissected out for further analyses. Asphyxial cardiac arrest
was induced as described earlier [58,59]. Head and body
temperature, and blood gases were maintained in the normal
range throughout the experiment. Sham animals were exposed to
isoflurane identical to the experimental groups. Rats were
sacrificed at 1 h post-ROSC and the hippocampus was dissected
out and used for further analysis.
Preparation of homogenate and isolation of
mitochondria from rat hippocampus
Hippocampal mitochondria were isolated as described earlier
with minor modifications [4]. Total mitochondria were isolated
from the last pellet using nitrogen compression [60]. All
mitochondrial isolation procedures were carried out at 4uC.
Hippocampal synaptosomes were isolated as described earlier
[60,61]. Percoll density gradient was used to separate synapto-
somes. Oxygen glucose deprivation (an in vitro model of ischemia)
was induced by incubating synaptosomes in glucose deprived
medium as described earlier [60,62]. During standardization, we
induced OGD of 30, 60 and 90 min and measured cytochrome c.
We used 60 min of OGD for all experiments since cytochrome c
release reached plateau at 60 min (80%, 114% and 110% at 30,
60 and 90 min of OGD, respectively). At the end of 60 min of
OGD, mitochondria were isolated from synaptosomes using a
nitrogen bomb [63]. Control synaptosomes were incubated in
glucose medium containing bubbled with air at 30uC.
Ex vivo dPKC activation and inhibition
Inhibition of dPKC was induced by pre-incubating synapto-
somes with either tat carrier peptide or dV1-1 (dPKC inhibitor)
(1 mM final concentration) for 15 min at room temperature (KAI
Pharmaceuticals Inc., South San Francisco, CA, USA) [64,65].
Tat carrier peptide or dV1-1 was also present during OGD.
Activation of dPKC was induced by pre-incubating synaptosomes
with either tat carrier peptide or ydRACK (dPKC activator)
(1 mM final concentration) for 15 min at room temperature.
Immunoprecipitation and Western blotting
Immunoprecipitation was carried out using rabbit polyclonal
anti-PLS3 (Imgenex, San Diego, CA, USA) or rabbit polyclonal
anti- Bax (Santa Cruz biotechnology, Santa Cruz, CA, USA) and
protein A sepharose beads (Sigma, St. Louis, MO, USA) as per
manufacturer’s instructions. The resulting immunoprecipitate was
used for immunoblotting (see below) with subsequent probing
using mouse monoclonal anti-phosphothreonine (Cell Signaling
Technology, Danvers, MA, USA) with normalization to total
protein levels using the primary antibody. Antibodies used were
rabbit polyclonal anti-dPKC (Calbiochem, Gibbstown, NJ, USA),
mouse monoclonal anti-cytochrome c (BD Pharmingen, San Jose,
CA, USA), mouse monoclonal anti-cytochrome c oxidase subunit
IV (Invitrogen, Carlsbad, CA, USA), or mouse monoclonal anti-b-
actin (Sigma, St. Louis, MO, USA) antibodies and species specific
secondary antibodies. The digitized immunoblots were subjected
to densitometric analyses [60].
Phosphoprotein staining, sample extraction from gel,
and mass spectrometry
Proteins were separated from mitochondrial samples on a 4–
20% acrylamide gel (Invitrogen Corporation, Carlsbad, CA).
Phosphoproteins in the gradient gel were identified using Pro-Q
Diamond Phosphoprotein Gel Stain (Molecular Probes Inc.,
Carlsbad, CA) as per manufacturer’s instructions and subsequently
stained with Coomassie blue (Pierce Biotechnology, Rockford, IL)
to confirm equal protein loading. For protein identification, gel
slices were excised and digested in situ with sequencing-grade
trypsin (Promega Biosciences, Inc., Madison, WI). Samples were
then processed for protein identification as described earlier [66].
Statistical analysis
The results are expressed as mean 6 SEM. Statistical
significance was determined with Student’s t-test when there were
two experimental groups. For more than two groups, statistical
evaluation of the data was performed using ANOVA test, followed
by Dunnett’s post hoc test with p,0.05 considered significant.
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